| Autor: |
Fernyhough, L. J., Hock, B. D., Taylor, J., Pearson, J., Ganly, P. |
| Předmět: |
|
| Zdroj: |
Internal Medicine Journal; Feb2013, Vol. 43 Issue 2, p130-137, 8p, 2 Charts, 2 Graphs |
| Abstrakt: |
Aim This retrospective study compares the overall survival ( OS) of multiple myeloma ( MM) patients following treatment at a New Zealand hospital over a period in which novel therapies were available but restricted, almost exclusively, to thalidomide as a second-line therapy. Methods Clinical, laboratory and OS data were collected on 361 MM patients who were treated at Christchurch Hospital during 2000-2010. Patients were subdivided according to the clinical criteria used to determine front-line treatment decisions. Older patients (age ≥66, n = 180) generally received standard-dose chemotherapy without autologous stem cell transplant ( SCT) and formed one group. Younger patients were further subdivided according to whether they received autologous SCT ( n = 89), allogeneic SCT ( n = 24) or no SCT ( n = 68). Results Older patients had a significantly shorter OS ( P < 0.0001) than younger patients (median OS = 25 vs 78 months) however treated. Analysis of relative survival demonstrated that the increased mortality of older patients was greater than that attributable to normal ageing. Younger patients who received no transplant had a significantly shorter OS ( P < 0.0001) than those who received autologous SCT or allogeneic SCT with 5-year survivals of 38%, 70% and 72% respectively. Use of novel therapies was significantly higher in younger than older patients (60% vs 47%, P = 0.011). Conclusions The front-line treatment groupings of hospital MM patients had significantly different survivals. The OS of SCT ineligible patients remains poor despite the introduction of thalidomide. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text